Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Anchiano Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Anchiano Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Anchiano Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Anchiano Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Anchiano Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Anchiano Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Anchiano Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Anchiano Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Anchiano Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Anchiano Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Anchiano Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Anchiano Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Frank G. Haluska, M.D. Ph.D., serves as President and Chief Executive Officer at BioCancell Ltd. He also serves as Chief Executive Officer at Anchiano Therapeutics Ltd since October 2016 and also serves as its Director. He serves as the President at Anchiano Therapeutics Ltd. He currently serves on the board of at Vedantra Pharmaceuticals, Inc. Dr. Haluska served as the Chief Medical Officer of Ariad Haluska Inc., since June 2010 until May 6, 2016 and served as its Senior Vice President of Clinical R&D since January 2012 until May 6, 2016. Dr. Haluska served as Vice President of Clinical Research & Development at Ariad Pharmaceuticals Inc. since June 2010. He served as Senior Medical Director of Ariad Pharmaceuticals Inc. since November 2007 until July 2010. He is a recognized authority on the targeted therapy of kinase abnormalities in solid tumors. Most recently, he served as a senior faculty Member in the departments of medicine and genetics at Tufts University School of Medicine, where he served as Clinical Director and Deputy Director of the Tufts-New England Medical Center Cancer Center. He is also major in the Medical Corps of the United States Air Force and the Massachusetts Air National Guard. Dr. Haluska has to ARIAD fifteen years of experience in medical research and clinical oncology at centers of excellence, including the Dana-Farber Cancer Institute and Massachusetts General Hospital Cancer Center. He received his M.D. and Ph.D. from the University Of Pennsylvania School Of Medicine and his A.B. from Harvard University. He did postgraduate training at Massachusetts General Hospital, the Dana-Farber Cancer Institute and the Massachusetts Institute of Technology.
Frank's compensation has increased whilst company is loss making.
Frank's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Anchiano Therapeutics management team is about average.
CFO & COO
Senior Vice President of Clinical Development & Data Sciences
Co-Founder & Chief Scientific Officer
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Anchiano Therapeutics board of directors is less than 3 years, this suggests a new board.
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.